Richard G Moore

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/286253/publications.pdf

Version: 2024-02-01

53	3,653	257450	182427
papers	citations	24 h-index	51 g-index

53	53	53	3521
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Evolution and Transformation of Uterine Transplantation: A Systematic Review of Surgical Techniques and Outcomes. Journal of Reconstructive Microsurgery, 2022, 38, 429-440.	1.8	1
2	Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial. Journal of Clinical Oncology, 2022, 40, 2138-2147.	1.6	40
3	Stacking Machine Learning Algorithms for Biomarker-Based Preoperative Diagnosis of a Pelvic Mass. Cancers, 2022, 14, 1291.	3.7	7
4	Identification of a Vitamin-D Receptor Antagonist, MeTC7, which Inhibits the Growth of Xenograft and Transgenic Tumors In Vivo. Journal of Medicinal Chemistry, 2022, 65, 6039-6055.	6.4	3
5	Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study. Gynecologic Oncology, 2022, 166, 36-43.	1.4	18
6	A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clinical Cancer Research, 2021, 27, 2734-2741.	7.0	7
7	HE4 Overexpression by Ovarian Cancer Promotes a Suppressive Tumor Immune Microenvironment and Enhanced Tumor and Macrophage PD-L1 Expression. Journal of Immunology, 2021, 206, 2478-2488.	0.8	13
8	Analysis of serum HE4 levels in various histologic subtypes of epithelial ovarian cancer and other malignant tumors. Tumor Biology, 2021, 43, 355-365.	1.8	4
9	The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genes. Scientific Reports, 2020, 10, 8558.	3.3	16
10	A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.. Journal of Clinical Oncology, 2020, 38, 6003-6003.	1.6	42
11	Biomarker lead time for predicting progression in women with ovarian cancer compared to imaging.. Journal of Clinical Oncology, 2020, 38, e18074-e18074.	1.6	0
12	Novel Small Molecule MEK Inhibitor URML-3881 Enhances Cisplatin Sensitivity in Clear Cell Ovarian Cancer. Translational Oncology, 2019, 12, 917-924.	3.7	7
13	Multiple biomarker algorithms to predict epithelial ovarian cancer in women with a pelvic mass: Can additional makers improve performance?. Gynecologic Oncology, 2019, 154, 150-155.	1.4	25
14	Human Epididymis Secretory Protein 4 (HE4) Compromises Cytotoxic Mononuclear Cells via Inducing Dual Specificity Phosphatase 6. Frontiers in Pharmacology, 2019, 10, 216.	3.5	7
15	Septin-2 is overexpressed in epithelial ovarian cancer and mediates proliferation via regulation of cellular metabolic proteins. Oncotarget, 2019, 10, 2959-2972.	1.8	8
16	Interval robotic cytoreduction following neoadjuvant chemotherapy in advanced ovarian cancer. Journal of Robotic Surgery, 2018, 12, 245-250.	1.8	13
17	Receipt of adjuvant endometrial cancer treatment according to race: anÂNRG Oncology/Gynecologic Oncology Group 210 Study. American Journal of Obstetrics and Gynecology, 2018, 219, 459.e1-459.e11.	1.3	12
18	HE4 Promotes Events Associated with Metastatic Ovarian Cancer Via Regulation of the Extracellular Matrix. FASEB Journal, 2018, 32, 804.1.	0.5	0

#	Article	IF	Citations
19	Assessment of serum HE4 levels throughout the normal menstrual cycle. American Journal of Obstetrics and Gynecology, 2017, 217, 53.e1-53.e9.	1.3	6
20	Predictors for lymph nodes involvement in low risk endometrial cancer. Journal of Obstetrics and Gynaecology, 2017, 37, 514-518.	0.9	8
21	Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence. Journal of the National Cancer Institute, 2017, 109, djw251.	6.3	28
22	Human Epididymis Protein 4 Promotes Events Associated with Metastatic Ovarian Cancer via Regulation of the Extracelluar Matrix. Frontiers in Oncology, 2017, 7, 332.	2.8	23
23	The cranberry flavonoids PAC DP-9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells. International Journal of Oncology, 2015, 46, 1924-1934.	3.3	62
24	Tetrathiomolybdate inhibits mitochondrial complex IV and mediates degradation of hypoxia-inducible factor-1Î± in cancer cells. Scientific Reports, 2015, 5, 14296.	3.3	38
25	Tetrathiomolybdate mediates cisplatin-induced p38 signaling and EGFR degradation and enhances response to cisplatin therapy in gynecologic cancers. Scientific Reports, 2015, 5, 15911.	3.3	14
26	Templated polymers enable selective capture and release of lysophosphatidic acid in human plasma via optimization of non-covalent binding to functional monomers. Analyst, The, 2015, 140, 7572-7577.	3.5	2
27	Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/Gynecologic Oncology Group 210 Trial. Journal of the National Cancer Institute, 2015, 107, .	6.3	32
28	Associations between etiologic factors and mortality after endometrial cancer diagnosis: The NRG Oncology/Gynecologic Oncology Group 210 trial. Gynecologic Oncology, 2015, 139, 70-76.	1.4	23
29	Predictive factors for the presence of malignant transformation of pelvic endometriosis. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 185, 23-27.	1.1	22
30	Antitumor Activity of 3-Indolylmethanamines 31B and PS121912. Anticancer Research, 2015, 35, 6001-7.	1.1	7
31	Combining clinical assessment and the Risk of Ovarian Malignancy Algorithm for the prediction of ovarian cancer. Gynecologic Oncology, 2014, 135, 547-551.	1.4	12
32	A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer. American Journal of Obstetrics and Gynecology, 2014, 211, 68.e1-68.e8.	1.3	17
33	Long-term follow-up of vulvar cancer patients evaluated with sentinel lymph node biopsy alone. Gynecologic Oncology, 2014, 133, 416-420.	1.4	48
34	HE4 (WFDC2) gene overexpression promotes ovarian tumor growth. Scientific Reports, 2014, 4, 3574.	3.3	79
35	Etiologic heterogeneity in endometrial cancer: Evidence from a Gynecologic Oncology Group trial. Gynecologic Oncology, 2013, 129, 277-284.	1.4	185
36	PT19c, Another Nonhypercalcemic Vitamin D2 Derivative, Demonstrates Antitumor Efficacy in Epithelial Ovarian and Endometrial Cancer Models. Genes and Cancer, 2013, 4, 524-534.	1.9	11

#	Article	IF	Citations
37	Evaluation and Management of Women Presenting with a Pelvic Mass. Current Obstetrics and Gynecology Reports, 2012, 1, 10-15.	0.8	2
38	Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. American Journal of Obstetrics and Gynecology, 2012, 206, 349.e1-349.e7.	1.3	117
39	Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. American Journal of Obstetrics and Gynecology, 2012, 206, 351.e1-351.e8.	1.3	116
40	Efficacy of a Non-Hypercalcemic Vitamin-D2 Derived Anti-Cancer Agent (MT19c) and Inhibition of Fatty Acid Synthesis in an Ovarian Cancer Xenograft Model. PLoS ONE, 2012, 7, e34443.	2.5	16
41	Utility of Tumor Marker HE4 to Predict Depth of Myometrial Invasion in Endometrioid Adenocarcinoma of the Uterus. International Journal of Gynecological Cancer, 2011, 21, 1.	2.5	58
42	Evaluation of the Diagnostic Accuracy of the Risk of Ovarian Malignancy Algorithm in Women With a Pelvic Mass. Obstetrics and Gynecology, 2011, 118, 280-288.	2.4	224
43	Current clinical use of biomarkers for epithelial ovarian cancer. Current Opinion in Oncology, 2010, 22, 492-497.	2.4	41
44	Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. American Journal of Obstetrics and Gynecology, 2010, 203, 228.e1-228.e6.	1.3	219
45	Current state of biomarker development for clinical application in epithelial ovarian cancer. Gynecologic Oncology, 2010, 116, 240-245.	1.4	92
46	A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecologic Oncology, 2009, 112, 40-46.	1.4	702
47	The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecologic Oncology, 2008, 108, 402-408.	1.4	594
48	Isolated sentinel lymph node dissection with conservative management in patients with squamous cell carcinoma of the vulva: A prospective trial. Gynecologic Oncology, 2008, 109, 65-70.	1.4	62
49	Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecologic Oncology, 2008, 110, 196-201.	1.4	184
50	Incidence of metastasis to the ovaries from nongenital tract primary tumors. Gynecologic Oncology, 2004, 93, 87-91.	1.4	188
51	Pathologic evaluation of inguinal sentinel lymph nodes in vulvar cancer patients: a comparison of immunohistochemical staining versus ultrastaging with hematoxylin and eosin staining. Gynecologic Oncology, 2003, 91, 378-382.	1.4	68
52	Sentinel node identification and the ability to detect metastatic tumor to inguinal lymph nodes in squamous cell cancer of the vulva. Gynecologic Oncology, 2003, 89, 475-479.	1.4	96
53	Vulvar Epithelioid Sarcoma in Pregnancy. Gynecologic Oncology, 2002, 85, 218-222.	1.4	34